Zobrazeno 1 - 10
of 100
pro vyhledávání: '"recurrent GBM"'
Autor:
Sohyun Hwang, Jaejoon Lim, Haeyoun Kang, Ju-Yeon Jeong, Je-Gun Joung, Jinhyung Heo, Daun Jung, Kyunggi Cho, Hee Jung An
Publikováno v:
Cell & Bioscience, Vol 13, Iss 1, Pp 1-16 (2023)
Abstract Background Recurrent glioblastoma multiforme (GBM) is a highly aggressive primary malignant brain tumor that is resistant to existing treatments. Recently, we reported that activated autologous natural killer (NK) cell therapeutics induced a
Externí odkaz:
https://doaj.org/article/9bcc41a2725b4215ae1f35aee73aa482
Autor:
Mohummad A. Rahman, Jorunn Brekke, Victoria Arnesen, Marianne H. Hannisdal, Andrea G. Navarro, Andreas Waha, Lars Herfindal, Cecilie B. Rygh, Eirik Bratland, Petter Brandal, Judit Haasz, Leif Oltedal, Hrvoje Miletic, Arvid Lundervold, Stein A. Lie, Dorota Goplen, Martha Chekenya
Publikováno v:
Immunity, Inflammation and Disease, Vol 8, Iss 3, Pp 342-359 (2020)
Abstract Background Glioblastoma (GBM) is an aggressive malignant brain tumor where median survival is approximately 15 months after best available multimodal treatment. Recurrence is inevitable, largely due to O6 methylguanine DNA methyltransferase
Externí odkaz:
https://doaj.org/article/6667890c0064459f9f27a9dbdca009cb
Autor:
Sabrina Heynckes, Karam Daka, Pamela Franco, Annette Gaebelein, Jan Hendrik Frenking, Roberto Doria-Medina, Irina Mader, Daniel Delev, Oliver Schnell, Dieter Henrik Heiland
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background In recent years, PD-1/PD-L1 immune checkpoint inhibitors have improved cancer therapy in many tumor types, but no benefit of immune checkpoint therapy has been found in glioblastoma multiforme (GBM). Based on the results of our ea
Externí odkaz:
https://doaj.org/article/eb8b96f01e0c4d828266b0d73c52ad85
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Charles Cobbs, Edward McClay, J Paul Duic, L Burt Nabors, Donna Morgan Murray, Santosh Kesari
Publikováno v:
CNS Oncology, Vol 8, Iss 1 (2019)
Aim: Evaluation of the Nativis Voyager® device in patients with recurrent glioblastoma (rGBM). Materials & methods: Voyager is a noninvasive, nonthermal, nonionizing and portable investigational device which delivers ultra-low radio frequency energy
Externí odkaz:
https://doaj.org/article/fa3e4c93c1534b618bb11c7cceb3aec3
Autor:
Viktorija Juric, Heiko Düssmann, Martine L. M. Lamfers, Jochen H. M. Prehn, Markus Rehm, Brona M. Murphy
Publikováno v:
Cells, Vol 10, Iss 5, p 1182 (2021)
Glioma stem cells (GSCs) are tumour initiating cells which contribute to treatment resistance, temozolomide (TMZ) chemotherapy and radiotherapy, in glioblastoma (GBM), the most aggressive adult brain tumour. A major contributor to the uncontrolled tu
Externí odkaz:
https://doaj.org/article/3b8338b04ed24df380b6d3f6a10d0004
Autor:
Bryan G. Harder, Mylan R. Blomquist, Junwen Wang, Anthony J. Kim, Graeme F. Woodworth, Jeffrey A. Winkles, Joseph C. Loftus, Nhan L. Tran
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Glioblastoma (GBM) is one of the most common, deadly, and difficult-to-treat adult brain tumors. Surgical removal of the tumor, followed by radiotherapy (RT) and temozolomide (TMZ) administration, is the current treatment modality, but this regimen o
Externí odkaz:
https://doaj.org/article/0c2fd300726c436ebd4d086c12e334b5
Autor:
Patrizia Ciammella, Salvatore Cozzi, Andrea Botti, Lucia Giaccherini, Roberto Sghedoni, Matteo Orlandi, Manuela Napoli, Rosario Pascarella, Anna Pisanello, Marco Russo, Francesco Cavallieri, Maria Paola Ruggieri, Silvio Cavuto, Luisa Savoldi, Cinzia Iotti, Mauro Iori
Publikováno v:
Cancers; Volume 14; Issue 19; Pages: 4604
Glioblastoma multiforme (GBM) is the most aggressive astrocytic primary brain tumor, and concurrent temozolomide (TMZ) and radiotherapy (RT) followed by maintenance of adjuvant TMZ is the current standard of care. Despite advances in imaging techniqu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b2846ddbb33c6c2853132c3421e9f90
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Marianne Hannisdal, Dorota Goplen, Cecilie Brekke Rygh, Eirik Bratland, Stein Atle Lie, Mohummad Aminur Rahman, Arvid Lundervold, Victoria Smith Arnesen, Jorunn Brekke, Martha Chekenya, Petter Brandal, Judit Haász, Hrvoje Miletic, Lars Herfindal, Leif Oltedal, Andreas Waha, Andrea Gras Navarro
Publikováno v:
Immunity, Inflammation and Disease
Immunity,Inflammation and Disease
Immunity, Inflammation and Disease, Vol 8, Iss 3, Pp 342-359 (2020)
Immunity,Inflammation and Disease
Immunity, Inflammation and Disease, Vol 8, Iss 3, Pp 342-359 (2020)
Background Glioblastoma (GBM) is an aggressive malignant brain tumor where median survival is approximately 15 months after best available multimodal treatment. Recurrence is inevitable, largely due to O6 methylguanine DNA methyltransferase (MGMT) th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e82af2c755744d9ceaecb8c07b7fa70
http://europepmc.org/articles/PMC7416034
http://europepmc.org/articles/PMC7416034